This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nguyen, M. H.
Right arrow Articles by Graybill, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nguyen, M. H.
Right arrow Articles by Graybill, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 05 1997, 1120-1123, Vol 41, No. 5
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis

MH Nguyen, LK Najvar, CY Yu and JR Graybill
University of Florida College of Medicine, Gainesville VA Medical Center, USA. nguyen.med@shands.ufl.edu

This study elucidates the role of combined fluconazole and flucytosine as therapy for cryptococcosis in the murine model of meningitis. Three strains of Cryptococcus neoformans for which the range of fluconazole MICs was wide--2 microg/ml (susceptible strain), 8 microg/ml (moderately susceptible strain), and 32 microg/ml (resistant strain)-- were used for infection. One day postinfection, the mice were randomized into eight treatment groups: placebo; flucytosine (40 mg/kg of body weight/day); fluconazole at 3 mg/kg/day (low dosage), 10 mg/kg/day (moderate dosage), or 20 mg/kg/day (high dosage); and combined flucytosine and fluconazole at low, moderate, or high doses of fluconazole. Three major findings were demonstrated: (i) correlation between the MICs for the isolates and the in vivo effectiveness of fluconazole as assessed by the reduction in cryptococcal brain burden, (ii) a dose-response curve (a higher dose of fluconazole was significantly more efficacious than a lower dose [P < 0.001]), and (iii) synergism between fluconazole and flucytosine (therapy with a combination of fluconazole and flucytosine was superior to therapy with either agent alone [P < 0.01]).


This article has been cited by other articles:

  • Schwarz, P., Dromer, F., Lortholary, O., Dannaoui, E. (2006). Efficacy of Amphotericin B in Combination with Flucytosine against Flucytosine-Susceptible or Flucytosine-Resistant Isolates of Cryptococcus neoformans during Disseminated Murine Cryptococcosis. Antimicrob. Agents Chemother. 50: 113-120 [Abstract] [Full Text]  
  • Serena, C., Fernandez-Torres, B., Pastor, F. J., Trilles, L., Lazera, M. d. S., Nolard, N., Guarro, J. (2005). In Vitro Interactions of Micafungin with Other Antifungal Drugs against Clinical Isolates of Four Species of Cryptococcus. Antimicrob. Agents Chemother. 49: 2994-2996 [Abstract] [Full Text]  
  • Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., Ghannoum, M. A. (2005). Combination Treatment of Invasive Fungal Infections. Clin. Microbiol. Rev. 18: 163-194 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Schimizzi, A. M., Maracci, M., Giannini, D., Carle, F., Scalise, G. (2004). Posaconazole and Amphotericin B Combination Therapy against Cryptococcus neoformans Infection. Antimicrob. Agents Chemother. 48: 3312-3316 [Abstract] [Full Text]  
  • Barchiesi, F., Spreghini, E., Maracci, M., Fothergill, A. W., Baldassarri, I., Rinaldi, M. G., Scalise, G. (2004). In Vitro Activities of Voriconazole in Combination with Three Other Antifungal Agents against Candida glabrata. Antimicrob. Agents Chemother. 48: 3317-3322 [Abstract] [Full Text]  
  • Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., Rex, J. H. (2004). Combination Antifungal Therapy. Antimicrob. Agents Chemother. 48: 693-715 [Full Text]  
  • Dannaoui, E., Lortholary, O., Dromer, F. (2004). In Vitro Evaluation of Double and Triple Combinations of Antifungal Drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob. Agents Chemother. 48: 970-978 [Abstract] [Full Text]  
  • Schwarz, P., Dromer, F., Lortholary, O., Dannaoui, E. (2003). In Vitro Interaction of Flucytosine with Conventional and New Antifungals against Cryptococcus neoformans Clinical Isolates. Antimicrob. Agents Chemother. 47: 3361-3364 [Abstract] [Full Text]  
  • Bialek, R., Weiss, M., Bekure-Nemariam, K., Najvar, L. K., Alberdi, M. B., Graybill, J. R., Reischl, U. (2002). Detection of Cryptococcus neoformans DNA in Tissue Samples by Nested and Real-Time PCR Assays. CVI 9: 461-469 [Abstract] [Full Text]  
  • Barchiesi, F., Schimizzi, A. M., Najvar, L. K., Bocanegra, R., Caselli, F., Di Cesare, S., Giannini, D., Di Francesco, L. F., Giacometti, A., Carle, F., Scalise, G., Graybill, J. R. (2001). Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 45: 1355-1359 [Abstract] [Full Text]  
  • Furukawa, K., Sasaki, H., Pollard, R. B., Suzuki, F. (2000). Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans. J Antimicrob Chemother 46: 443-450 [Abstract] [Full Text]  
  • Barchiesi, F., Schimizzi, A. M., Caselli, F., Novelli, A., Fallani, S., Giannini, D., Arzeni, D., Di Cesare, S., Di Francesco, L. F., Fortuna, M., Giacometti, A., Carle, F., Mazzei, T., Scalise, G. (2000). Interactions between Triazoles and Amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44: 2435-2441 [Abstract] [Full Text]  
  • Barchiesi, F., Gallo, D., Caselli, F., Di Francesco, L. F., Arzeni, D., Giacometti, A., Scalise, G. (1999). In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 44: 65-70 [Abstract] [Full Text]  
  • Lortholary, O., Nicolas, M., Soreda, S., Improvisi, L., Ronin, O., Petitjean, O., Dupont, B., Tod, M., Dromer, F. (1999). Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing. J Antimicrob Chemother 43: 817-824 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
  • White, T. C., Marr, K. A., Bowden, R. A. (1998). Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance. Clin. Microbiol. Rev. 11: 382-402 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»